Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

Background: Neuroblastic tumors (NBTs) originate from a block in the process of differentiation. Histologically, NBTs are classified in neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Current therapy for high-risk (HR) NB includes chemotherapy, surgery, radiotherapy, and ant...

Full description

Bibliographic Details
Main Authors: Jaume Mora, Alicia Castañeda, Maria Cecilia Colombo, Maite Gorostegui, Fernando Gomez, Salvador Mañe, Vicente Santa-Maria, Moira Garraus, Napoleon Macias, Sara Perez-Jaume, Oscar Muñoz, Juan Pablo Muñoz, Ignasi Barber, Mariona Suñol
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
neuroblastoma
anti-GD2 immunotherapy
naxitamab
differentiation
functional MRI
functional imaging
Online Access:https://www.mdpi.com/2072-6694/13/6/1264

Internet

https://www.mdpi.com/2072-6694/13/6/1264

Similar Items